新闻中心
News Center
Olanzapine Tablets Passed the Consistency Evaluation of Generic Drugs
Release Time
2022-06-21 16:25
Recently, Olanzhi® Olanzapine Tablets (specification: 5mg*20 tablets, 10mg*20 tablets), which are generally distributed by Shenzhen Foncoo Pharmaceutical Co., Ltd., passed the national generic drug quality and efficacy consistency evaluation. Olanzhi is produced by Dr. Reddy Laboratories Ltd. of India using US cGMP standards, but the price is similar to other olanzapine generics. In 2011, Olanzhi was approved by the US FDA and was the first generic olanzapine drug to be marketed in the United States, and its market share exceeded that of the original olanzapine; in Europe, 1 out of every 2 patients taking olanzapine Oran's. Oranzhi submitted generic drug consistency evaluation data in China in October 2018, and passed the review in early September 2019. So far, in addition to the original research olanzapine in the domestic market, Olanzhi is the only olanzapine tablet certified by the US FDA, EU EMEA, and China's three major systems of consistency evaluation.
Next page
Next page
Related News
Sponsored by the Chinese Medical Association and the Psychiatry Branch of the Chinese Medical Association, and organized by the Chongqing Medical Association, the Psychiatry Branch of the Chongqing Medical Association, the First Affiliated Hospital of Chongqing Medical University, and the University City Hospital Affiliated to Chongqing Medical University The conference and the Academic Conference on Child and Adolescent Psychiatry were successfully held at Chongqing Yuelai International Conference Center from December 21 to 24, 2021.
2022-05-25
On October 15, 2021, Foncoo Pharmaceutical donated 100,000 yuan in cash to the "Gu Xueqiu Pharmacy Education Fund" public welfare student aid project of the Beijing Renren Public Welfare Foundation-Shenyang Pharmaceutical University.
2022-05-25
Foncoo Pharmaceutical's corporate culture 5.0 was officially released
Official announcement! Seriously, don't be distracted!
2022-05-25
On October 29-31, 2021, the 16th National Academic Conference on Psychiatric Hospital Management, hosted by the Chinese Hospital Association and the Chinese Hospital Association Psychiatric Hospital Branch, was held in Chongqing.
2022-05-25
Recently, "Bupropion Hydrochloride Sustained-Release Tablets (II) (150mg, 300mg)", exclusively sold by Pangu Pharmaceuticals (Mainland China), was approved by the State Drug Administration and deemed to have passed the consistency evaluation. The product, developed by Shanghai Xuantai Pharmaceuticals, was previously approved by the FDA in August 2017 and was marketed in the United States.
2022-05-25
Foncoo Pharmaceutical participated in the 9th China Schizophrenia Forum
From October 22 to 24, 2021, the "Ninth China Schizophrenia Forum" was grandly held in Wuhan. The theme of this forum is "Infection, Inflammation and Schizophrenia".
2022-05-25
Contact Us：
Room 1502-1506, Building D2, Nanshan iPark, No.1001 Xue Yuan Boulevard, Nanshan District, Shenzhen, China.
Follow Us
© COPYRIGHT 2021 Shenzhen Foncoo Pharmaceutical Co., Ltd. ALL RIGHTS RESERVED